Evidence map›Paper›PMID 26239088›Full record

Trial reportBlood2015

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.

Junichi Kiyasu, Hiroaki Miyoshi, Akie Hirata, Fumiko Arakawa, Ayako Ichikawa, Daisuke Niino, Yasuo Sugita, Yuji Yufu, Ilseung Choi, Yasunobu Abe and 7 more

Abstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 279 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
279citing papers in PubMed, 4 pooled it
31.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

279 citing papers in PubMed, 4 syntheses or guidelines pooled it, 476 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  6. Trial
  7. Journal for immunotherapy of cancer · 2025
    Trial
  8. Trial
  9. Safety and efficacy of durvalumab with R-CHOP or RInternational journal of hematology · 2022
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. METTL3-dependent mJournal of translational medicine · 2026
    Article
  16. Review
  17. Article
  18. Review
  19. PD-L1/Cancers · 2026
    Article
  20. Article

219 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Junichi KiyasuDepartment of Pathology, Kurume University, School of Medicine, Kurume, Japan; Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Hematology, Iizuka Hospital, Iizuka, Japan;
Hiroaki MiyoshiDepartment of Pathology, Kurume University, School of Medicine, Kurume, Japan;
Akie HirataDepartment of Geriatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
Fumiko ArakawaDepartment of Pathology, Kurume University, School of Medicine, Kurume, Japan;
Ayako IchikawaDepartment of Pathology, Kurume University, School of Medicine, Kurume, Japan;
Daisuke NiinoDepartment of Pathology, Kurume University, School of Medicine, Kurume, Japan;
Yasuo SugitaDepartment of Pathology, Kurume University, School of Medicine, Kurume, Japan;
Yuji YufuDepartment of Hematology, Iizuka Hospital, Iizuka, Japan;
Ilseung ChoiDepartment of Hematology, National Kyushu Cancer Center, Fukuoka, Japan;
Yasunobu AbeDepartment of Hematology, National Kyushu Cancer Center, Fukuoka, Japan;
Naokuni UikeDepartment of Hematology, National Kyushu Cancer Center, Fukuoka, Japan;
Koji NagafujiDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan; and.
Takashi OkamuraDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan; and.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka, Japan.
Ryoichi TakayanagiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
Motoaki ShiratsuchiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
Koichi OhshimaDepartment of Pathology, Kurume University, School of Medicine, Kurume, Japan;
Kurume University · JPKyushu University · JPNational Hospital Organization Kyushu Cancer Center · JPAso Iizuka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death ligand 1 (PD-L1) is expressed on both select diffuse large B-cell lymphoma (DLBCL) tumor cells and on tumor-infiltrating nonmalignant cells. The programmed cell death 1 (PD-1)/PD-L1 pathway inhibits host antitumor responses; however, little is known about how this pathway functions in the tumor microenvironment. The aim of this study was to determine the clinicopathological impact of PD-L1(+) DLBCL. We performed PD-L1/PAX5 double immunostaining in 1253 DLBCL biopsy samples and established a new definition of PD-L1(+) DLBCL. We also defined the criteria for microenvironmental PD-L1(+) (mPD-L1(+)) DLBCL (ie, PD-L1(-) DLBCL in which PD-L1(+) nonmalignant cells are abundant in the tumor microenvironment). Of the 273 patients whose clinical information was available, quantitative analysis of PD-1(+) tumor-infiltrating lymphocytes (TILs) was performed. The prevalence rates of PD-L1(+) and mPD-L1(+) DLBCL were 11% and 15.3%, respectively. Both PD-L1(+) and mPD-L1(+) DLBCL were significantly associated with non-germinal center B-cell (GCB) type and Epstein-Barr virus positivity. The number of PD-1(+) TILs was significantly higher in GCB-type tumors and lower in mPD-L1(-) and PD-L1(+) DLBCL. Patients with PD-L1(+) DLBCL had inferior overall survival (OS) compared with that in patients with PD-L1(-) DLBCL (P = .0009). In contrast, there was no significant difference in OS between mPD-L1(+) and mPD-L1(-) DLBCL (P = .31). The expression of PD-L1 maintained prognostic value for OS in multivariate analysis (P = .0323). This is the first report describing the clinicopathological features and outcomes of PD-L1(+) DLBCL. Immunotherapy targeting the PD-1/PD-L1 pathway should be considered in this distinct DLBCL subgroup.

Indexed as

Gene Expression Regulation, NeoplasticTumor MicroenvironmentAdolescentAdultAgedAged, 80 and overB7-H1 AntigenBiopsyDisease-Free SurvivalFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm ProteinsProgrammed Cell Death 1 ReceptorB7-H1 AntigenCD274 protein, humanNeoplasm ProteinsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID26239088
PMCPMC4635115
OpenAlexW1135493307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.